Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.

Liang JA, Sun LM, Lin MC, Chang SN, Sung FC, Muo CH, Kao CH.

Oncologist. 2012;17(7):986-91. doi: 10.1634/theoncologist.2011-0464. Epub 2012 Jun 20.

2.

5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.

Chou CH, Lin CL, Lin MC, Sung FC, Kao CH.

J Endocrinol Invest. 2015 Jul;38(7):799-805. doi: 10.1007/s40618-015-0263-1. Epub 2015 Mar 17.

PMID:
25778849
3.

A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia.

Lin WL, Hsieh YW, Lin CL, Sung FC, Wu CH, Kao CH.

Clin Endocrinol (Oxf). 2015 Apr;82(4):503-8. doi: 10.1111/cen.12599. Epub 2014 Nov 4.

PMID:
25158777
4.

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

Bartsch G, Rittmaster RS, Klocker H.

World J Urol. 2002 Apr;19(6):413-25. Review.

PMID:
12022710
5.

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

Bartsch G, Rittmaster RS, Klocker H.

Eur Urol. 2000 Apr;37(4):367-80. Review.

PMID:
10765065
6.

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.

DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF.

J Manag Care Spec Pharm. 2016 Oct;22(10):1204-14. doi: 10.18553/jmcp.2016.22.10.1204.

7.

The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.

Cindolo L, Fanizza C, Romero M, Pirozzi L, Autorino R, Berardinelli F, Schips L.

World J Urol. 2013 Jun;31(3):665-71. doi: 10.1007/s00345-012-1000-4. Epub 2012 Dec 14.

PMID:
23239103
8.

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.

Kuiper JG, Bezemer ID, Driessen MT, Vasylyev A, Roehrborn CG, Penning-van Beest FJ, Herings RM.

BMC Urol. 2016 Aug 31;16(1):53. doi: 10.1186/s12894-016-0170-6.

9.

5-alpha-reductase inhibitors and the risk of diabetes mellitus: A nationwide population-based study.

Lee SS, Yang YW, Tsai TH, Kuo YH, Chuang HY, Lee CC, Hsieh TF.

Prostate. 2016 Jan;76(1):41-7. doi: 10.1002/pros.23097. Epub 2015 Sep 22.

PMID:
26390988
11.
12.

Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.

Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A.

Cancer Causes Control. 2011 Aug;22(8):1121-31. doi: 10.1007/s10552-011-9787-7. Epub 2011 Jun 11.

13.

Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM.

Am J Epidemiol. 2008 Dec 15;168(12):1416-24. doi: 10.1093/aje/kwn272. Epub 2008 Oct 21.

14.

Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.

Helfand BT, Blackwell RH, McVary KT.

J Urol. 2010 Jul;184(1):218-23. doi: 10.1016/j.juro.2010.03.020. Epub 2010 May 16.

PMID:
20483154
15.

5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.

Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF.

JAMA Intern Med. 2014 Aug;174(8):1301-7. doi: 10.1001/jamainternmed.2014.1600.

16.

Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.

Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM.

Am J Epidemiol. 2011 Jun 15;173(12):1419-28. doi: 10.1093/aje/kwq493. Epub 2011 May 3. Erratum in: Am J Epidemiol. 2011 Dec 15;174(12):1425.

17.

5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.

Rittmaster RS.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):389-402. doi: 10.1016/j.beem.2008.01.016. Review.

PMID:
18471794
18.

Five-alpha-reductase Inhibitors for prostate cancer prevention.

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091. doi: 10.1002/14651858.CD007091. Review.

PMID:
18425978
19.

Association between 5-alpha reductase inhibition and risk of hip fracture.

Jacobsen SJ, Cheetham TC, Haque R, Shi JM, Loo RK.

JAMA. 2008 Oct 8;300(14):1660-4. doi: 10.1001/jama.300.14.1660.

PMID:
18840839

Supplemental Content

Support Center